To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 256 participants.

Also called NCT05101135

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 256 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05101135
Other papers using this trial's data
  • Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial Diabetes & metabolism journal, 2024-09 DOI, PubMed 38310875, PMC11449822 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05101135. Randomized; double masking; primary purpose treatment. Start 2021-11-17 (actual); primary completion 2022-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
JT-001
Intervention (Drug)
JT-001 Placebo
Lead sponsor
Jeil Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05101135
Content hash
33ebcdab79be32126e45e4ff6acb07bfd41e7020475fa179dcdbe1bd5f275a20